# The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

> **NCT04676035** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer Patients

## Interventions

- **DRUG:** Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680

## Key facts

- **NCT ID:** NCT04676035
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676035, "The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04676035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*